Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10584486
Filing Date		2007-04-09
First Named Inventor	Sleep	
Art Unit		1636
Examiner Name	Kette	r
Attorney Docket Numb	er	11069-US-PCT

	U.S.PATENTS Remove							
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5783385	A	1998-07-21	Treco			
	2	6939676	B2	2005-09-06	Burke			
	3	5571691	A	1996-11-05	Conneely			
	4	5637504	A	1997-06-10	Hinchliffe			
	5	5773245	A	1998-06-30	Wittrup			
	6	6451559	B1	2002-09-17	Schreier			
If you wis	h to add	additional U.S. Paten	t citatio	n information pl	ease click the Add button.	Add		
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		

/James Ketter/ 11/13/2011

Application Number		10584486		
Filing Date		2007-04-09		
First Named Inventor Sleep				
Art Unit		1636		
Examiner Name	Ketter			
Attorney Docket Number	ar .	11069-US-PCT		

	1		20030226155	A1	2003-12-04		Sadeghi				
	2		20070275889	A1	2007-11-29		Sleep				
	3		20080261861	A1	2008-10-23		Sleep				
	4		20080206811	A1	2008-08-28		Shodai				
If you wis	h to a	id a	dditional U.S. Publ	ished Ap	plication	citation	ı n information p	lease click the Add	butto	on. Add	
					FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No		reign Document ımber³	Countr Code ²		Kind Code4	Publication Date	Name of Patentee Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	199	940003617	wo		A1	1994-02-17	Toschko			
	2	199	980056928	wo		A1	1998-12-17	Harmsen			
	3	200	03066085	wo		A1	2003-08-14	Mertins			
	4	200	040015113	wo		A2	2004-02-19	Jurs			
	5	200	050078105	wo	wo		2005-08-25	Sedgwick			

/James Ketter/ 11/13/2011

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10584486
Filing Date		2007-04-09
First Named Inventor	Sleep	
Art Unit		1636
Examiner Name	Ketter	
Attorney Docket Numb	er	11069-US-PCT

	6	20060067511	wo	A1	2006-06-29	Finnis			
If you wis	h to a	l dd additional Foreign P	I atent Document	citation	information p	lease click the Add buttor	Add	_	
			NON-PATE	NT LIT	ERATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No								
	1	Breslow et al 2008, Nat	Breslow et al 2008, Nat Methods 5 (8), 711-718						
	2	Dolinski 1997, Proc Nat	Dolinski 1997, Proc Nati Aad Sci USA 94, 13093-13098						
	3	Jin et al 2008, Mol Biol Cell 19, 284-296							
	4	Kurihara et al 1994, J Cell Biol 126 (4), 911-23							
	5	Lawrence et al 2004, Mol Cel Biol 24 (8), 3307-3323							
	6	Liang et al 2007, Mol Biol Cell 18, 4741-4749							
	7	Palmer et al 2003, J Ce	II Sci 116, 2361-2	373					
	8	Yoshikawa et al 2008,	FEMS Yeast Res	9 (1), 32	-44				

/James Ketter/

11/13/2011

Application Number		10584486
Filing Date		2007-04-09
First Named Inventor Sleep		
Art Unit		1636
Examiner Name	Ketter	
Attorney Docket Numb	er	11069-US-PCT

9	AB Vector -ProFold- ERI 2004, Internet Article -	
10	AB Vector Technol 2011, Internet Article	
11	Belanger et al 1994, Swissprot Acces No P36953	
12	Boeke et al 1987, Methods enzymol 154, 164-175	
13	Brachmann et al 1998, Yeast 30 (14), 115-132	
14	Brown et al 1990, Swissprot acces no P14639	
15	Cassady et al 1990, Swissprot Access No P19121	
16	Fassler 2004, EMBO Rep 5 (1), 28-29	
17	Giaever et al 2002, Nature 418, 387 -391	
18	Hilger 1996, Swissprot Access No P49064	
19	Hilger 1996, Swissprot Access No P49822	

/James Ketter/

RE	
NT	
99)	

Filing Date

Art Unit

First Named Inventor

Examiner Name

Application Number

10584486 2007-04-09

Sleep 1636

Ketter

Attorney Docket Number

11069-US-PCT

20	Ho et al 1994, Swissprot access no P35747	
21	Jones et al 2003, Physiol Genomics 16, 107-118	
22	McReynoids et al 1986, Swissprot Acess No P01012	
23	Nishizawa et al 1989, Appl Microbiol Biotech 32, 317-322	
24	Panaretou et al 2002, Mol Cell 10, 1307-1318	
25	Patterson et al 1995, Swissprot Access No P39090	
26	Roberts et al 2005, Swissprot Acces No O73860	
27	Rose et al 1987, Gene 60, 237 - 243	
28	Sahasrabudhe et al 1998, Prot Exp Purif 14, 425-433	
29	Schreuder et al 1996, Vaccine 14(5), 383-388	
30	Shevchuk et al 2004, Nucl Acids Res 32 (2), e19	

Application Number		10584486
Filing Date		2007-04-09
First Named Inventor	Sleep	
Art Unit		1636
Examiner Name	Ketter	
Attorney Docket Numb	er	11069-US-PCT

31	Syed et al 1996, Swissprot Access No P49065	
32	Tonkool P 2001, Acta Biotechnol 21(2), 189-193	
33	Van Reeth 1999, Swissprot Acces No O89020	
34	Vob et al, 2003, J Biotechnol 105, 205-213	
35	Watkins et al 1997, Swiss prot acces no Q28522	
36	Wolkowicz et al 2004, Methods Mol Biol 246, 391-411	
37	NCB1 Accession No. NM001018416 (2005)	
38	Accession No. P36424 (2010)	
39	Accession No. Q5R9A4 (2010)	
40	GenBank Accession No. U16761 (1994)	
41	Finnis et al 1993, Eur J Biochem 212, 201-210	

/James Ketter/

Application Number		10584486
iling Date		2007-04-09
First Named Inventor Sleep		
Art Unit		1636
xaminer Name Ketter		
Hornov Dooket Numb		11000 HE DOT

	42	Broach et al 1982, Cell 29, 227-234	
	43	Cashmore et al 1986, Mol Gen Genet 203, 154-162	
	44	Christis et al 2008, FEBS 275, 4700-4727	
	45		
	46	Creasey et al 2003, Mol Microbiol 47(1), 209-221	
	47	DeMolder et al 1994, J Biotechnology 32, 179-189	
	48	Denecke et al 1991, The Plant Cell 3, 1025-1035	
	49	Hamilton et al 1996, J Biol Chem 271(48), 30610-30613	
	50	Lee et al 2001, J Biochem Mol Biology 34(2), 102-108]
If you wish	n to a	dd additional non-patent literature document citation information please click the Add button Add	
		EXAMINER SIGNATURE	
Examiner	Signa	ature /James Ketter/ Date Considered 11/13/2011	
*EVAMINE	ED: 1-	sitial if reference considered, whether or not citation is in conferences with MRED 600. Draw line through a	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 Application Number
 10584486

 Filing Date
 2007-04-09

 First Named Inventor
 Sleep

 Art Unit
 1636

 Examiner Name
 Ketter

 Attorney Docket Number
 11069-US-PCT

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ³ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

10584486 2007-04-09

First Named Inventor Sleen 1636

Ketter

Attorney Docket Number 11069-US-PCT

CERTIFICATION STATEMENT

Application Number

Examiner Name

Filing Date

Art Unit

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael W. Krenicky, Reg. # 45411/	Date (YYYY-MM-DD)	2011-11-03
Name/Print	Michael Krenicky	Registration Number	45411

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about Individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an iscus patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.